TrialGynecologic oncology2014

A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Lainie P Martin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.